<DOC>
	<DOCNO>NCT03050411</DOCNO>
	<brief_summary>Epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) , include gefitinib demonstrate excellent effect treatment non-small cell lung cancer ( NSCLC ) patient EGFR mutation . However , patient initially sensitive drug eventually become resistance . Apatinib highly selective VEGFR2 inhibitor reduces angiogenesis tumor efficiently . In study , investigator aim explore efficacy reasonable dosage apatinib combine EGFR-TKI advanced non-squamous non-small cell lung cancer EGFR-TKI resistance .</brief_summary>
	<brief_title>Apatinib Combine With EGFR-TKI Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Primary Outcome Measure : efficacy reasonable dosage combination apatinib EGFR-TKI advance non-squamous non-small cell lung cancer EGFR-TKI resistance . Secondary Outcome Measures : Progression free survival , overall survival , Side effect .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Obtain informed consent . 2 . Histologically cytologically confirm , inoperable , recurrence metastasis advance nonsmall cell lung cancer ( TNM Stage ⅢB stage Ⅳ ) , take EGFRTKI longer 6 month appear disease progression . 3 . At least one measurable lesion ( helical CT scan long diameter ≥10mm , meet requirement standard Response Evaluation Criteria In Solid Tumors（RESCIST） version 1.1 ) . 4 . Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :02 . 5 . Aged 18 75 year ( 18 75 year include ) . 6 . Life expectancy ≥12 week . 7 . Adequate bone marrow reserve organ function follow : Absolute neutrophils count ( ANC ) ≥1.5 x 10 9th power/L ( band neutrophil segment neutrophil ) , platelets &gt; 100 x 10 9th power/L Hb≥90g/L . Hepatic : total bilirubin less equal 1.5 time upper limit normal ( ULN ) . Alkaline phosphatase ( AP ) , alanine transaminase ( ALT ) aspartate transaminase ( AST ) less equal 3.0 time ULN ( less equal 5 time ULN case know liver involvement . Renal : Serum Creatinine less equal 1.25 time upper limit normal ( ULN ) . 8 . Have history hypertension ( le 135/85mmHg ) . 9 . Females childbearing potential must negative serum pregnancy test . Sexually active male female ( childbearing potential ) willing practice contraception study . 1 . Do meet criterion . 2 . Prior treatment VEGFR tyrosine kinase inhibitor VEGFR target agent . 3 . Unhealed toxicity prior anticancer treatment ( CTCAE Level 1 ) surgery . 4 . Symptomatic Central Nervous System ( CNS ) metastases . 5 . Uncontrolled hypertension ( systolic ≥140mmHg and/or diastolic ≥90mmHg medication treatment ) . 6 . Clinical uncontrolled active infection , acute pneumonia , active hepatitis B C ( prior hepatitis B history , despite medication treatment control , HBV DNA≥500copies ≥100IU/ml ) , etc . 7 . Arterial thrombosis venous thrombosis 6 month , disposition evidence thrombosis/bleeding 2 month ( despite severity ) , hemoptysis 2 week ( bright red blood , 1/2 teaspoon ) . 8 . Stroke transient ischemic attack ( TIA ) 12 month . 9 . Unhealed skin lesion , surgical site , injury , severe mucous membrane ulcer bone fracture . 10 . Cardiac function evaluation : LVEF &lt; 50 % , recent history MI 6 month , severe/unstable angina coronary bypass surgery , cardiac insufficiency ≥ NYHA 2 . 11 . Prior malignant disease 5 year ( except carcinoma situ cervix , non melanoma skin cancer , localized prostate cancer Gleason ≤6 ) . 12 . Documented history neurological psychiatric disorder , include epilepsy dementia . 13 . Recent active digestive disease duodenal ulcer , ulcerative colitis , ileus , ect. , intestinal perforation , intestine fistula , condition may lead gastrointestinal bleed perforation regiment investigator ' discretion . 14 . Difficulty swallow know malabsorption . 15 . A history organ transplantation longterm immunosuppressive medication . 16 . Take part new drug clinical trial within one month take part trial . 17 . Pregnant lactate woman . 18 . A history anaphylaxis apatinib analogue and/or excipient drug study . 19 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>EGFR-TKI resistance</keyword>
	<keyword>Apatinib</keyword>
	<keyword>anti-angiogenesis drug</keyword>
</DOC>